Plain-English translation of NCT05859191 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking at specific immune cells called iNKT cells in people with lupus to understand how they contribute to the disease. Researchers want to learn whether these cells help control lupus or make it worse, and how a receptor called FcRn might affect their function. By studying blood samples from lupus patients alongside healthy volunteers, scientists hope to uncover new insights that could lead to better treatments.
Lupus is an autoimmune disease where the body's immune system attacks its own tissues, and doctors have noticed that certain immune cells are often reduced in lupus patients. However, no one fully understands whether these cells are protective or harmful, or how they could be targeted with new therapies. This study exists to fill that knowledge gap and potentially open doors to new treatment approaches.
You likely qualify if…
You likely don't qualify if…
If you join, you would simply donate three extra tubes of blood during your regular lupus clinic visits or hospital appointments—the same times you already get blood work done. There are no extra visits required, and the blood draw takes just a few minutes. Researchers will analyze your samples to look at immune cells and compare them with samples from healthy volunteers to understand how lupus affects these cells.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
France
Sponsor
University Hospital, Tours
Collaborators
Research Center for Respiratory Diseases, Inserm U1100
Enrollment target
~50 participants
Started
July 2023
Primary completion
July 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yanis RAMDANI
CHRU de Tours
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.